News & Events
CAMBRIDGE, Mass. and CROMWELL, Conn., May 04, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific models for challenging diseases, and Biological Industries USA (BI-USA), a subsidiary of Biological Industries (Israel), today announced a new sales and marketing agreement to promote custom stem cell services. The partnership combines BI-USA’s strength in stem cell culture media and manufacturing with Cellaria’s comprehensive Stem Cell Services program, which includes industry leading RNA reprogramming and custom differentiation services.
BioreclamationIVT Signs Exclusive Agreement To Distribute Cellaria Cell Models And Media For Cancer Research
WESTBURY, N.Y., April 13, 2017 (PRNewswire) — BioreclamationIVT, a leading provider of biospecimens and related services, has signed a new distribution partnership agreement with Cellaria, LLC. According to the terms of the agreement, BioreclamationIVT will have exclusive market and distribution rights to Cellaria’s novel cancer cell lines and cancer culture media in the United States and Canada and non-exclusive rights to sell the products globally. The agreement expands the availability of Cellaria’s offerings to a broader range of potential customers via an established distribution partner with existing relationships inside the biopharmaceutical industry.
CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the expansion of its offerings to include a suite of stem cell services. The initiative advances Cellaria’s mission to provide more accurate patient and disease-specific cell models to help researchers focus and accelerate their research and discovery efforts.
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
CAMBRIDGE, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the release of two new ovarian cancer cell models and one breast cancer cell model. With these additions to its model library, Cellaria expands on its mission to provide researchers with more accurate models of the tumor, enabling more relevant and impactful research and accelerated discovery efforts.
The Official Platinum Co-Sponsors of Powering Precision Health 2016 are Quanterix and Cellaria Biosciences. Quanterix is renowned for its ground-breaking tools in high definition diagnostics for life science research, in-vitro diagnostics, companion diagnostics, and blood screening. Cellaria Biosciences creates breakthrough oncology models that ultimately lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure.
In this era of personalized medicine, oncologists want as much information as they can get about the genetic makeup of a patient’s tumor. A number of companies, including Kendall Square startup
Cellaria Bio, are trying to grow tumor models in the lab.
For 50 years, scientists have ignored widespread cell contamination, compromising medical research. Why are they so slow to fix it?
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.